Právní předpis byl sestaven k datu 20.12.2013.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. x. x x. 46/2008 Sb. x. x. x xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 97/2012 Sb. m. x. x Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 12. listopadu 2012 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno schválení xxxxxx znění Přílohy X - Xxxxxxx xxxxxxxxxx látek a xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx1).
S novým xxxxxx Přílohy I xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Úmluvy dne 1. ledna 2013 x tímto xxxx xxxxxxxxx x platnost x xxx Českou xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x platnost xxxxxxxx platit znění Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxx xx 1. ledna 2012 a xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x její překlad xx xxxxxxx xxxxxx xx xxxxxxxxx současně.
1) Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx přijatá xxx 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXX X
XXXXXX XXXXXXXXXX LÁTEK X XXXXX DOPINGU XXX ROK 2013
XXXXXXX XXXXXXXXXXXXX KODEX
Xxxxxx xx 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx xxxxx budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx látek xx xxxxxx X1, X2, S4.4, S4.5 x S6(a) x Xxxxxxxxxx xxxxx X1, X2 x X3.
| &xxxx;
XXXXX X XXXXXX XXXXXXXX XXXXX
(XXX SOUTĚŽI X XXXX XXXXXX)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx stadiu xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxxxxxxxx léky), je xxxxxxxx xxxxx.
X1. XXXXXXXXXX LÁTKY
Anabolické xxxxx jsou xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* AAS, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); kalusteron; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prostanozol (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); quinbolon; stanozolol; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.
(b) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx a xxxxxxx, xxx xx x xxxxxxxx xxxxx na xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
|
|
5α-androstan-3α,17β-diol
|
|
|
5α-androstan-3β,17α-diol
|
epi-dihydrotestosteron
|
|
5α-androstan-3β,17β-diol
|
epitestosteron
|
|
androst-4-en-3α,17α-diol
|
3α-hydroxy-5αandrostan-17-on
|
|
androst-4-en-3α,17β-diol
|
3β-hydroxy-5αandrostan-17-on
|
|
androst-5-en-3β,17α-diol
|
7α-hydroxy-DHEA
|
|
androst-5-en-3α,17α-diol
|
7β-hydroxy-DHEA
|
|
androst-5-en-3α,17β-dioI
|
7-keto-DHEA
|
|
androst-5-en-3β,17α-diol
|
19-norandrosteron
|
|
4-androstendiol (androst-4-en-3β,17β-diol)
|
19-noretiocholanolon
|
2. Xxxxxxx anabolické xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx na xx.
| &xxxx;
Xxx xxxxx xxxxxxx této xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, kterou xxxx xxxx xxxxxxxx schopno xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx k látce, xxxxxx xxxx tělo xxxxxxxxxx přirozeně.
|
X2. XXXXXXXXX XXXXXXX, XXXXXXX FAKTORY X XXXXXXXX XXXXX
Následující xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (CG) a Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (GH), fibroblastové xxxxxxx faktory (XXXx), xxxxxxxxxxxx růstový xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (IGF-1), xxxxxxxxxx růstové xxxxxxx (XXX), růstový xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx růstové xxxxxxx ovlivňující syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, šlach x xxxxxx, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx vláken;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
X3. XXXX2- AGONISTÉ
Všichni xxxx-2 xxxxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. d- x x-), xxxx xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 mikrogramů xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx za 24 xxxxx) x salmeterolu xxxxx jsou xxxxxx x inhalaci v xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx v xxxx v xxxxxxxxxxx xxxxx xxx 1000 xx/xx a přítomnost xxxxxxxxxxx x xxxx x koncentraci vyšší xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx bude xxxxxxxxxx xx pozitivní xxxxxxxxxxx xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, že xxxxxxxxxx xxxxxxxx xxx způsoben xxxxxxxx terapeutické inhalační xxxxx nižší xxx xxxx xxxxxxx maximum.
X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxxx aromatáz, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-androsten-3,6,17-trion (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.
2. Selektivní xxxxxxxxxx estrogenových receptorů (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx myostatinu, ale xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx modulátory:
x) Xxxxxxxx;
x) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. GW 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx AMP x součinnosti x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx kinase (AMPK) xxxx agonists/ (xxxx. XXXXX)
X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, plasmaexpandery (xxxx. glycerol, nitrožilní xxxxxx xxxxxxxx, dextranu, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x podobnými xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Xxx xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx s xxxxxxxxxx xxxx jinou xxxxxxxxx látkou xx xxxxxxxxxx udělení xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx látku xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXXX X XXXX X XXXXXXXX KOMPONENTAMI
Zakázané xx xxxxxxxxxxx:
1. Xxxxxx xxxx znovuzavedení xxxxxxxxx, homologní xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx krvinek a xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx dodávky xxxxxxx, xxxxxxxxxx modifikované xxxxxxxxxxxxx produkty (xxxx.xxxxxx xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx ne x xxxxxxxx pouze xx xx. Xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.
3. Xxxxxxxxx forma xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. CHEMICKÁ A XXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, za xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, ale xx s omezením xxxxx xx xx.
2. Nitrožilní xxxxxx x/xxxx xxxxxxx více xxx 50 ml xx 6 hodin xxxx xxxxxxxx xxxxx xxxxxx legitimně xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxx nebo klinických xxxxxxxxxxxxx xxxxx.
M3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx sportovního xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Transfer xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx;
| &xxxx;
LÁTKY X METODY XXXXXXXX XXX XXXXXXX
|
Xxxxx xxxxxxxxx X0 xx X5 x X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx zakázané x xxxxxxxxxxx xxxxxxx:
XXXXXXXX XXXXX
S6. XXXXXXXXXXX
Všechna xxxxxxxxxxx xxxxxx xxxxx jejich xxxxxxxxxx xxxxxxxxx isomerů (xxxx. x- x x-) jsou xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx v případě xxxxxx místního použití x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx zahrnují:
(a) Xxxxxxxxxxxx stimulancia:
Xxxxxxxxx, xxxxxxxxxx, amfetaminil, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, famprofazon, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, fenproporex, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, kokain, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (d-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, p-methylamfetamin, xxxxxxxxxx, xxxxxxxxx.
Stimulancium, xxxxx xxxx výslovně uvedeno x tomto xxxxxxxx, xx Specifickou xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, fenkamfamin, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, metylefedrin****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, oktopamin, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, pseudoefedrin*****selegilin, xxxxxxxxxx, xxxxxxxxx, tuaminoheptan x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.
* Xxxxxxxxxxx xxxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, nikotin, xxxxxxxxx, xxxxxxxx) nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx xxxxxxxxxx (xxxx. xxxxx, xxxx xxxxxxxx) nebo xxxx podání xxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxx zakázáno.
*** Xxxxx je zakázaný xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx x methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 ml xxxx.
***** Xxxxxxxxxxxxx je xxxxxxx, xxxxx xxxx xxxxxxxxxxx x moči xx xxxxx než 150 mikrogramů xx xxxxxxxx
S7. NARKOTIKA
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx a xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
S8. XXXXXXXXXXX
Přírodní (xxxx. xxxxx, konopí x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, XXX073/ x XX-210) jsou xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X URČITÝCH SPORTECH
|
P1. XXXXXXX
Xxxxxxx (xxxxxx) je xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Detekce se xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo rozborem xxxx. Xxxxxxx hodnota xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Karate (XXX)
∙ Xxxxxxx xxxxxx x parašutismus(FAI)
∙ Xxxxxxxxxxx (XXXX)
∙ Motocyklový xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Pokud xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx zakázány xxxxx Xxx Soutěži v xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (FITA, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Lyžování (XXX) - xxxxx xx lyžích x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x xxxxxxxxx X-xxxxx x "xxx air"
∙ Xxxxxxx (XXXX, XXX) (zakázané xxxx Xxxx xxxxxx)
∙ Xxxxx (XXX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, bunolol, xxxxxxxxxx, xxxxxxx, karteolol, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, nadolol, xxxxxxxxxx, pindolol, propranolol, xxxxxxx, xxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx předpis č. 98/2013 Xx. x. x. xxxxx xxxxxxxxx xxxx 20.12.2013.
Právní xxxxxxx x. 98/2013 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx od 20.9.2014.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není aktualizováno, xxxxx se xxxx xxxxxx derogační xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.